Kyverna reports positive 1 — year KYSA — 8 trial data for miv — cel in stiff person syndrome

Kyverna reported positive one-year durability data for miv-cel in stiff person syndrome from its KYSA-8 registrational trial. Key trial endpoints were previously presented at AAN 2026; the full one-year dataset will be presented at MS Toronto on Oct. 21-23, 2026. Results showed sustained clinical benefit through one year, with most patients remaining off chronic immunotherapies and disability improvements holding up. Longer-term follow-up from the KYSA-6 Phase 2 portion in generalized myasthenia gravis showed durable responses out to as long as 1.5 years. No new high-grade safety signals were reported; the rolling BLA submission for SPS remains on track for completion in Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via (Ref. ID: 202609240600PRIMZONEFULLFEED9832549) on September 24, 2026, and is solely responsible for the info